USE OF COST-CONSEQUENCE MODELS IN MANAGED CARE

被引:0
|
作者
BLISSENBACH, HF [1 ]
机构
[1] DIVERSIFIED PHARMACEUT SERV,MINNEAPOLIS,MN
来源
PHARMACOTHERAPY | 1995年 / 15卷 / 05期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Functioning effectively as a pharmacy benefit manager has been defined as purchasing the best product at the lowest possible cost. In the simplest terms, this means purchasing discounted drugs; in the most complex terms, it means managing drug use. However, if the entire medical picture were analyzed, use of more expensive drugs might actually lower total direct medical costs. Currently, formulary decisions are based on both therapeutic necessity and cost. The decision to administer one drug rather than another is directed by community practice patterns and the final price. The availability of information to demonstrate differences, if any, in total treatment costs between the two agents would considerably enhance therapeutic decision making and would guide treatment by an outcome-based drug formulary. The question that requires an answer is centered on the value equation: Value = outcomes/cost. Before paying more for drug A than for drug B, the payer will demand to see value. When available, direct and indirect cost information will be applied to position drugs appropriately in a drug formulary.
引用
收藏
页码:S59 / S61
页数:3
相关论文
共 50 条
  • [31] Cost-consequence analysis of salvianolate injection for the treatment of coronary heart disease
    Pengxin Dong
    Hao Hu
    Xiaodong Guan
    Carolina Oi Lam Ung
    Luwen Shi
    Sheng Han
    Shuwen Yu
    [J]. Chinese Medicine, 13
  • [32] COST-CONSEQUENCE ANALYSIS OF CSII VS. MDI: A CANADIAN PERSPECTIVE
    Sadri, H.
    Bereza, B. G.
    Longo, C. J.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [33] Cost-consequence analysis evaluating multifaceted clinical pharmacist intervention targeting patient transitions of care from hospital to primary care
    Rasmussen, Maja Kjaer
    Ravn-Nielsen, Lene Vestergaard
    Duckert, Marie-Louise
    Lund, Mia Lolk
    Henriksen, Jolene Pilegaard
    Nielsen, Michelle Lyndgaard
    Eriksen, Christina Skovsende
    Buck, Thomas Croft
    Hansen, Morten Rix
    Pottegard, Anton
    Hallas, Jesper
    Kidholm, Kristian
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2019, 2 (02): : 123 - 130
  • [34] A COST-CONSEQUENCE MODEL FOR OCTREOTIDE LAR AS TREATMENT FOR METASTATIC MIDGUT NET
    Weber, M. M.
    Lister, J.
    Reichelt, C.
    Pulgar, S.
    Arora, S.
    Berenson, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 267 - 267
  • [35] Evaluating stroke early supported discharge using cost-consequence analysis
    Byrne, Adrian
    Chouliara, Niki
    Cameron, Trudi
    Geue, Claudia
    Lewis, Sarah
    Robinson, Thompson
    Langhorne, Peter
    Walker, Marion F.
    Fisher, Rebecca J.
    [J]. DISABILITY AND REHABILITATION, 2022, 44 (23) : 7127 - 7133
  • [36] Adherence, persistence and cost-consequence comparison of bimatoprost topical ocular formulations
    Alany, Raid G.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (09) : 1187 - 1189
  • [37] Cost, cost-consequence and cost-effectiveness evaluation of a practice change intervention to increase routine provision of antenatal care addressing maternal alcohol consumption
    Szewczyk, Zoe
    Reeves, Penny
    Kingsland, Melanie
    Doherty, Emma
    Elliott, Elizabeth
    Wolfenden, Luke
    Tsang, Tracey W.
    Dunlop, Adrian
    Searles, Andrew
    Wiggers, John
    [J]. IMPLEMENTATION SCIENCE, 2022, 17 (01)
  • [38] Cost, cost-consequence and cost-effectiveness evaluation of a practice change intervention to increase routine provision of antenatal care addressing maternal alcohol consumption
    Zoe Szewczyk
    Penny Reeves
    Melanie Kingsland
    Emma Doherty
    Elizabeth Elliott
    Luke Wolfenden
    Tracey W. Tsang
    Adrian Dunlop
    Andrew Searles
    John Wiggers
    [J]. Implementation Science, 17
  • [39] Cost-consequence of yoga respiratory training on respiratory muscle function in institutionalized elderly
    dels Angels Cebria i Iranzo, Maria
    Tortosa Chulia, Maria Angeles
    Igual Camacho, Celedonia
    Arnall, David Alan
    Tomas Miguel, Jose Manuel
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [40] A cost-consequence model comparing valaciclovir and aciclovir for the treatment of acute herpes zoster
    Grant, DM
    Mauskopf, JA
    Austin, R
    Chulay, JD
    Bell, L
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (04) : 108 - 108